|

BGB-21447 Clinical Trials

1 actively recruiting trial across 1 location

No change since June 2026

Pipeline

Phase 1: 1

Top Sponsors

  • BeOne Medicines1

Indications

  • Metastatic Breast Cancer1
  • HER2-negative Breast Cancer1
  • Hormone Receptor Positive Breast Cancer1
  • Breast Cancer1
  • Cancer1

Iowa City, Iowa1 trial

BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer

University of Iowa Hospitals and Clinics

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.